
Download
poster
143kb
pdf? |
|
Abstract for Automation of Multiplexed Cell-Based Viability and
Cytotoxicity Assays
Andrew Niles, Tracy Worzella and Michael Busch1
Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711
1CyBio AG, Goeschwitzer Strasse 40, 07745 Jena, Germany
Promega has developed homogeneous, non-lytic reagents that
measure the proportion of viable and non-viable cells in the same
assay well. Here we demonstrate the use of automation to perform
highthroughput and ultra-high throughput cell-based multiplexing
studies. We provide protocols and supporting data that demonstrate
the automation synergies of the assays with the CyBio CyBi®-Well
hardware. We show that complementary viability and cytotoxicity
measures have particular merit for normalizing data to reduce error
associated with cell clumping or identifying errors from
interferences due to test compounds or medium components. In
addition, we also demonstrate how the MultiTox assays can be further
multiplexed with a downstream assay, such as a Promega luminescent
assay or other spectrally distinct fluorescent assay method, to
measure caspase activation, reporter activity, or cell viability.
Specifically, we show how these novel assays can be further
multiplexed with downstream apoptosis assays in order to determine
mode of action effects. |